報價延遲最少15分鐘:2025/11/15 06:44 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
22.08 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.51/0.78
|
|
企業價值
6.50B
|
| 資產負債 |
|
每股賬面淨值
6.10
|
| 現金流量 |
|
現金流量率
0.04
|
| 損益表 |
|
收益
1.10B
|
|
每股收益
4.10
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/15 06:44 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa. |
